Drugs / V3-OVA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03556566 | Jul 2018 → Nov 2019 | ovarian cancer | Immunitor LLC | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V3-OVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03556566 ↗ |
| Modality | Vaccine | “Oral once daily pill of tableted vaccine (V3-OVA) containing ovarian cancer antigens administered for 3 months in 20 volunteers with ovarian cancer” NCT03556566 ↗ |
| Route | Oral | “Oral once daily pill of tableted vaccine (V3-OVA) containing ovarian cancer antigens administered for 3 months in 20 volunteers with ovarian cancer” NCT03556566 ↗ |